Research programme: spinal muscular atrophy therapeutics - Summit

Drug Profile

Research programme: spinal muscular atrophy therapeutics - Summit

Latest Information Update: 10 Feb 2009

Price : $50

At a glance

  • Originator VASTox
  • Class Small molecules
  • Mechanism of Action Survival of motor neuron 1 protein stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Spinal muscular atrophy

Most Recent Events

  • 10 Feb 2009 Discontinued - Preclinical for Spinal muscular atrophy in United Kingdom (PO)
  • 20 Jul 2007 VASTox is now called Summit
  • 21 Jul 2005 Preclinical trials in Spinal muscular atrophy in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top